Fresh updates. Clear comparisons. Even more clinical confidence.
You are going to love the latest updates to our Medication PocketCards—designed to help you make quick, informed decisions at the point of care.
GLP-1 & GIP Medications: Now Easier to Compare Than Ever
Our GLP-1 & GIP Meds PocketCard now includes two distinct versions—one for diabetes and one for weight management—so you can compare therapies at a glance.
Each version clearly outlines:
- Approved indications
- Medication action
- Efficacy
- Common side effects
This side-by-side approach makes it easier to individualize treatment decisions based on a person’s health profile, age, and comorbidities.
Oral Semaglutide for Weight Loss—Now Included
Big news in the GLP-1 world! Semaglutide is now available as an oral formulation for weight loss, and we’ve added it to the PocketCard.
- Rybelsus® remains the oral option approved for diabetes
- Oral semaglutide for weight loss is FDA-approved and included on the updated card
- Both formulations are approved to reduce cardiovascular risk
Just like Rybelsus, oral semaglutide for weight loss:
- Must be taken on an empty stomach
- With a small sip of water
- At least 30 minutes before food, beverages, or other medications
Farewell to Exenatide XR
It’s the end of an era. Exenatide XR (Bydureon®, Bcise®) has been discontinued.
The only remaining option is generic exenatide, administered twice daily—still available and noted on the updated PocketCard.
TZDs: A Farewell and a Comeback
We say goodbye to rosiglitazone and welcome a renewed appreciation for pioglitazone (Actos®).
Pioglitazone:
- Improves insulin resistance
- Lowers free fatty acids
- Is now indicated for hepatic steatosis or experienced a stroke
Research led by Dr. Ralph DeFronzo demonstrates that pioglitazone can shift fat from visceral to subcutaneous depots, improving metabolic health and liver outcomes.
Clinical pearls included on the card:
- Start low (15 mg) and titrate slowly
- Monitor for fluid retention and weight gain
- Check ankles and assess heart failure risk
- Avoid in individuals with CHF or high fracture risk
Importantly, pioglitazone is also indicated for people with prediabetes or diabetes who have experienced a stroke, as it significantly reduces the risk of recurrent stroke.
DPP-4 Inhibitors: A Smaller Role
DPP-4 inhibitors continue to decline in use due to lower efficacy and higher cost, and both alogliptin and sitagliptin carry an increased risk of heart-failure hospitalization.
That said, generic sitagliptin is once again available, so we’ve added it back to the PocketCard in the DPP-4 category—clearly labeled to support informed prescribing.
We Want to Hear From You 💜
- What do you think of the 2026 PocketCard updates?
- How do these cards support your clinical decision-making?
Your feedback helps us keep these tools practical, relevant, and clinician-approved. Click here to share your thoughts and observations with us!
Give us your feedback, and receive a FREE Medication PocketCard!
Learn More About Medications With Our Upcoming Courses
Level 2 | ADA Standards of Care Complete Review
Join us live on January 29th, 2026 at 11:30 AM PST!
Virtual DiabetesEd Training Conference
Join us on April 15th-17th, 2026!
